However, the efficacy and safety of iNO in intubated infants is already known [2] [6], and the purpose of this pilot trial was to show if iNO could be administered into an oxygen hood in the clinical setting.
The final products were administered into a marginal vein with 26G-needle syringe.
The solutions were administered into a peripheral vein at 60 ml kg 1per day for 4 days.
The PHEA-C16-iron oxide (0.45 mmol Fe, 25.13 mg Fe) was administered into a marginal vein of the rabbit's ear through the catheter.
Agents were administered into a freely running intravenous line.
Pharmacokinetic calculations are based on the assumption that drugs are administered into a central compartment and subsequently distributed into peripheral compartments.
The notion is widely-held that a vaccine is either tolerogenic or immunogenic based on whether the vaccine is administered into a quiescent or pro-inflammatory environment.
After 15 min of conjugation, the conjugate was administered into a complete growth medium overnight to a final QD concentration of 50 to 100 nM.
A bolus of 0.1 U/kg insulin (Human Actrapid Novo Nordiskk, Crawley, UK) was administered into a vein at the site of the antecubital fossa.
